Avalo Therapeutics, Inc. AVTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-8.95
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $59,000 | -$78.3M | — | — | $83.0M |
| 2024 | $441,000 | -$35.1M | — | — | $133.0M |
| 2023 | $1.9M | -$31.5M | — | — | $7.3M |
| 2022 | $18.1M | -$41.7M | — | -$26.8M | -$10.9M |
| 2021 | $5.4M | -$84.4M | — | -$71.0M | $23.1M |
| 2020 | $6.7M | -$63.5M | — | -$40.6M | $24.6M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Doyle Mittie | Chief Medical Officer | 2026-06-23 | Option exercise | 1,450 | $8.04 |
| Doyle Mittie | Chief Medical Officer | 2026-06-23 | Sell | 1,450 | $18.00 |
| Riley Jennifer | Chief Strategy Officer | 2026-06-10 | Tax withheld | 588 | $13.10 |
| VARKI PAUL | Chief Legal Officer | 2026-06-10 | Tax withheld | 1,081 | $13.10 |
| Sullivan Christopher Ryan | Chief Financial Officer | 2026-06-10 | Tax withheld | 138 | $13.10 |
| Doyle Mittie | Chief Medical Officer | 2026-06-10 | Tax withheld | 1,084 | $13.10 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -8.95 (distress)
- Working capital / assets 0.793
- Retained earnings / assets -3.851
- EBIT / assets -0.626
- Equity / liabilities 2.486
Source: SEC EDGAR filings · CIK 0001534120 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.